UpDoc Calls Its AI "Agentic." The FDA Calls It a "Calculator, Drug Dose.

The medical platform UpDoc recently secured FDA clearance for a clinical AI tool designed to assist adult patients with Type 2 diabetes. While company leadership framed the achievement as a milestone for AI agentic, official documentation clarifies that the software is categorized as a drug dose calculator rather than an autonomous diagnostic entity. The system utilizes a Large Language Model (LLM) to facilitate natural conversations with patients, yet the actual medication adjustments rely on deterministic logic strictly predefined by human doctors. This distinction highlights that the AI acts as a sophisticated interface for data collection and task automation, while clinical authority remains with the healthcare provider. Support for the technology stems from a Stanford clinical trial demonstrating that frequent AI interactions lead to faster dosage optimization and higher patient compliance. Despite its technical novelty, regulatory constraints ensure the AI cannot currently make independent medical judgments beyond the prescribed safety protocols established during initial setup.